In addition to BMI-1, WT1, and PR3, several other LAAs have been identified in CML patients such as RHAMM/CD186 and PRAME (82, 87–89) and thus represent candidate antigens for specific immunotherapies, with efficacy demonstrated in vaccination, including DC vaccination (90–93) and more recently, T cell receptor mimic antibodies (94, 95). Here, PRTN3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.